medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2005, Number 6

<< Back Next >>

Rev Mex Urol 2005; 65 (6)

Study to evaluate quality of life in patients with advanced prostate cancer, under treatment using the combination of buserelin plus nilutamide

Rodríguez-Rivera JA, Gabilondo-Navarro F, Vega-Serrano R, Jiménez-Ríos MA, Esteban-Maria J, Galán-Maraboto J, Calderón-Ferro F, Rivas-Gómez R, Gutiérrez GFA, Ayala C, Solana R

Language: Spanish
References: 28
Page: 398-406
PDF size: 70.85 Kb.


ABSTRACT

The rate of mortality by prostate neoplasms in Mexico exceeded the 70 by each 100,000 men older than 50 years of age, and although the prostate cancer is traditionally considered a disease of the old one, the modern methods of diagnosis have been in an early detection and many men are treated nowadays being physical and sexually active. The present therapies, that often include the medical or surgical castration, cause a deterioration in his physical activities and sexuality that finally repel in the emotional sphere, this has overturned the attention of the physicians and mainly of the patients to the quality of life. The objective of this study is to evaluate the quality of life in patients with advanced prostate cancer under treatment with hormone therapy using the combination of buserelin plus nilutamide. Material and methods. 98 patients with advanced prostate cancer was including within this study, the patients received nilutamide once at day and subcutaneous implants of buserelin acetate every two months, during 12 months, the questionnaires of quality of life were applied in month -1, 2, 6 and 12. Results. With respect to the quality of life, the patients referred a diminution in their normal daily activities, the micturition improved in obvious form, the patients showed a significant increase in their index of well-being in the visit four, that later decayed slightly but without arriving at the basal level, being a benefit in the short term, the sensations and the fatigue improves in visit four, to return at basal level in visit six. The sexuality index is reduced progressively in the time, the social life, is increased on the second month of treatment, statistically significant, to diminish later. The bone pain diminished, hitting importantly in the quality of life of the patients. Conclusion. The hormone therapy with the combination buserelina/nilutamide, is an alternative to the surgical castration, has shown effectiveness in the control of the advanced CaP, with times of long progression and life expectancy, the combination is well tolerated for long term and it does not increase the frequency of specific adverse events for each drug, improving the quality of life of the patients in the short term. The quality of the life is an important consideration for the men with prostate cancer. Although the treatment for the advanced prostate cancer can not prolong the life expectancy, has a deep impact in the quality of life related to the health.


REFERENCES

  1. Secretaría de Salud. Compendio de Cáncer 2000, Mortalidad/Morbilidad. Registro Histopatológico de Neoplasias Malignas. www.epi.org.mx, 2000.

  2. Caspar RF. Clinical uses of gonodothropin-releasing hormone analogues. Cadian Medical Association Journal 1991; 144: 153-8.

  3. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017-21.

  4. Studer UE, Altwein J, Bartsch G. Apekte zu den moglichen hormonollen Therapies des Prostatacarcinoms (Aspects to the possible hormonal therapies of prostatic cancer). Urologe A 1991; 30: 310-6.

  5. Peeling B. Phase III studies to compare goserelin (Zoladex) with orchiectomy and Diethylstilbestrol in the treatment of prostatic carcinoma. Urology 1989; 33(Suppl. 5): 45-52.

  6. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R, et al. Prevention of the transient adverse effects of gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321(7): 413-8.

  7. Schulze H, Senge T, Leitartikel: Das local fortgeschrittene Prostatacarcinom (Editorial: the locally advanced prostatic cancer) Urologe A 1992; 31(Suppl. 1): 2-3.

  8. Schulze H, Senge T. Influence of different types of antiandrogenes on luteinizing hormone-releasing analogue induced surge in patients with metastatic carcinoma of the prostate. Journal of Urology 1990; 144: 934-41.

  9. Labrie F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Monfette G, Laberge JG, Emond JP, Raynaud JP, Husson JM, Fazekas ATA. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and antiandrogen. J Steroid Biochem 1983; 19: 999.

  10. 10.DeVoogt HJ, Siciu S, Sylvester R, et al. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer. Journal of Urology 1989; 141: 883-8.

  11. 11.Soloway MS, Ishikawa S, Van der Zwaag R, Todd B. Prognostic factor in patients with advanced prostate cancer. Urology 1989; 33(Suppl. 5): 53-6.

  12. 12.Newling DW. What is progression in prostate cancer? The Prostate Supplement 1992; 4: 139-43.

  13. 13.Fossa SD, Aaronson N, Newling D, Van Cangh PJ. Quality of life and treatment of hormone resistant prostatic cancer. European Journal of Cancer 1990; 26 (11/12): 1133-6.

  14. 14.Fossa SD, Kasa ST, Calais de Silva F, Suciu S, Hengeveld M. Quality of life in prostate cancer patients. The prostate Supplement 1992; 4: 145-8.

  15. 15.Migliari R, Scarpa RM, Campus G, De Lisa A, Zucca I, D’Atri M, Serra A, Usai E. Evaluation of efficacy and tolerability of nilutamide and buserelin in the treatment of advanced prostate cancer. Arch Ital Urol Nefrol Androl 1991; 63 (1): 147-53.

  16. 16.Janknegt RA. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Cancer 1993; 72(Suppl. 12): 3874-7.

  17. 17.Bertagna C, De Gery A, Hucher M, Francois JP, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1,056 patients). Br J Urol 1994; 73 (4): 396-402.

  18. 18.Jimenez-Rios MA, Martinez-Cervera PF, Zonana-Farca E, Aragon-Castro MA, Sedano-Lozano A, Hernandez-Toriz N, Calderon-Ferro F, Valenzuela-Flores G, Vasquez-Ramos V, Suchil-Bernal L. Estudio de eficacia y seguridad de nilutamida en el tratamiento del cáncer de próstata avanzado. Rev Mex Urol 2003; 63: 130-6.

  19. 19.Du Plessis DJ. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology 1991; 37 (Suppl. 2): 20-4.

  20. 20.Huggins C, Hodges CV, Studies on prostatic cancer. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.

  21. 21.Curran D, Fossa S, Aaronson N, Kiebert G, Keuppens F, Hall R, et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997; 33: 1809.

  22. 22.Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE Jr. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207.

  23. 23.Herr HW, O’Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 1743.

  24. 24.Litwin MS, Shpall AI, Dorey F, Nguyen TH. Quality of life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998; 21: 327.

  25. 25.Fiet J, Dore JC, Go AL, Ojasoo T, Raynaud JP. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. Prostate 1993; 23(4): 291-313.

  26. 26.Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169(5): 1742-4.

  27. 27.Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999; (4): i-x, 1-246, 11-36, passim.

  28. 28.Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol 2003; 169: 1653-61.




2020     |     www.medigraphic.com